Seattle, WA, April 02, 2026 (GLOBE NEWSWIRE) — RYVYL Inc. (NASDAQ: RVYL) (“RYVYL” or the “Company”), and RTB Digital Inc.’s (Roundtable) CEO, James Heckman, announced today that the merger was approved at the Company’s Special Meeting of Shareholders held on April 1, 2026. The approval removes the final corporate hurdle to complete the merger, and, subject to Nasdaq approval of Roundtable’s initial listing application, which has been filed, establishes the foundation to list the combined company on Nasdaq as RTB Digital Inc., expected to be listed under the ticker symbol RTB. The transaction is anticipated to consummate imminently. “We are grateful for the outcome of today’s Special Meeting and appreciate RYVYL stockholders’ support for the merger,” said Heckman, founder and CEO of Roundtable. “In anticipation of bringing...

Paris, April 02, 2026 ANNUAL FINANCIAL REPORT 2025 In accordance with the regulatory requirements in force, Sfil announces that the French version of its Annual Financial Report 2025 was filed with the Autorité des Marchés Financiers (AMF) on April 02, 2026, and that it can be obtained from its website: https://sfil.fr/resultats-et-publications/ The English version of the Annual Financial Report 2025 will be available around mid-April 2026 on the website: https://sfil.fr/en/results-and-publications/AttachmentRFA Sfil 2025 Communiqué mise à dispo EN

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, highlighting a critical unmet therapeutic need LPP marks the fourth indication in brepocitinib’s expanding late-stage development program Multiple lines of evidence, including strong mechanistic rationale and clinically meaningful results in an investigator-initiated placebo-controlled study of brepocitinib in LPP, support rapid development of brepocitinib in this indication A seamless Phase 2b/3 potentially registrational trial of brepocitinib in LPP enrolled its first subjects in March 2026 Immunovant’s Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint;...

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, highlighting a critical unmet therapeutic need LPP marks the fourth indication in brepocitinib’s expanding late-stage development program Multiple lines of evidence, including strong mechanistic rationale and clinically meaningful results in an investigator-initiated placebo-controlled study of brepocitinib in LPP, support rapid development of brepocitinib in this indication A seamless Phase 2b/3 potentially registrational trial of brepocitinib in LPP enrolled its first subjects in March 2026DURHAM, N.C., April 02, 2026 (GLOBE NEWSWIRE) — Priovant today announced a new Phase 2b/3 clinical program...

ATHENS, Greece, April 02, 2026 (GLOBE NEWSWIRE) — TOP Ships Inc. (the “Company”), an international owner and operator of modern, fuel efficient “ECO” tanker vessels, announced today that its annual report on Form 20-F for the year ended December 31, 2025 (the “Annual Report”) has been filed with the U.S. Securities and Exchange Commission (the “Commission”). The Annual Report may be accessed through the Company’s website, www.topships.org, or on the website of the Commission, www.sec.gov. About the Company TOP Ships Inc. is an international owner and operator of ocean-going vessels focusing on modern, fuel-efficient eco tanker vessels transporting crude oil, petroleum products (clean and dirty) and bulk liquid chemicals. For more information about TOP Ships Inc., visit its website: www.topships.org. Cautionary Note Regarding...

HONG KONG, April 02, 2026 (GLOBE NEWSWIRE) — Futu Holdings Limited (“Futu” or the “Company”) (Nasdaq: FUTU), a leading tech-driven online brokerage and wealth management platform, today announced that its board of directors approved a cash dividend of US$0.325 per ordinary share, or US$2.6 per American Depositary Share (“ADS”), payable in U.S. dollars (the “Dividend”) to holders of ordinary shares and holders of ADSs of record as of the close of business on April 16, 2026, New York time. The aggregate amount of the Dividend will be approximately US$365 million. The Dividend to be paid to the Company’s ADS holders through the depositary bank will be subject to the terms of the deposit agreement. The payment date is expected to be on or around April 29, 2026 for holders of ordinary shares and holders of ADSs. About Futu Holdings Limited Futu...

Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findings Patients in the TED studies demonstrated greater levels of proptosis improvement from baseline after the initial 12-week high-dose period than after the following 12-week low-dose period, supporting the benefit of deeper IgG suppression. The hyperthyroid patients in the TED studies showed similar response rates of thyroid hormone normalization to those seen in the batoclimab Phase 2 study in Graves’ disease Immunovant remains focused on rapid advancement of IMVT-1402 in multiple indicationsDURHAM, N.C., April 02, 2026 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases,...